Cholera remains a serious health problem, as well as an economic problem, in several regions of the world, with an annual death toll of at least 100,000 (33) . Until comparatively recently, only Vibrio cholerae strains of O1 serogroup had shown the potential to establish cholera epidemics. An inactivated vaccine, comprising killed whole cells supplemented with the isolated B subunit of the cholera toxin, has proven effective against endemic and epidemic disease caused by V. cholerae O1 (10) . However, in 1992 a second serogroup (O139) with epidemic potential emerged (2, 12, 19) . Although high levels of serum bactericidal and intestinal immunoglobulin A (IgA) antibody to lipopolysaccharide (LPS) can be detected in patients convalescing from O1 disease (25, 26) , such responses do not appear to confer protection against V. cholerae O139 (1, 12, 20) . This may partly explain the rapid spread of this serogroup to several Asian countries (4, 19) , which prompted attempts to develop bivalent O1/O139 vaccines (3, 13) .
One major obstacle to preclinical evaluation of new vaccine candidates is the fact that only humans are naturally susceptible to V. cholerae infection. Several animal models have been developed, the most widely used being the infant mouse cholera model (IMCM) (6, 31) . Significantly, observations made in this model have paralleled later findings in human volunteer trials (6, 29) , but a major disadvantage is that the model only allows the evaluation of passive immunity. Acquired immunity to V. cholerae has instead been primarily studied in models such as the removable intestinal tie-adult rabbit diarrhea model (1, 28) , but this system is more expensive and much less convenient. In several respects, adult mice are ideal for preclinical studies, since they are inexpensive and readily housed and manipulated; their immune system has been extensively studied; and the availability of congenic knockout strains assists elucidation of the nature of protective host immunity.
It has been known for 40 years that oral administration of pathogenic V. cholerae to germfree adult mice results in sustained gut colonization (27) . More recently, it has been reported that, once infected, these animals can be housed conventionally, significantly simplifying this approach (7) . However, the initial cost of the animals remains an obstacle to their widespread use, as do, more significantly, concerns about their immunological maturity. Finally, although germfree mice can be used for studies of active immunity, such studies cannot culminate in direct challenge of the vaccinated animals, since upon transition to conventional housing they become refractory to colonization. Nevertheless, experience with germfree mice indicates that the normal gut flora is a major impediment to successful colonization by V. cholerae.
This prompted us to examine the feasibility of using streptomycin (Sm) to deplete the intestinal flora, thereby making conventional adult mice receptive to colonization by V. cholerae. Although there are reported instances of V. cholerae being fed to Sm-treated mice (14, 18) , these studies did not address this possibility. In the present context we envisaged a two-phase adult mouse cholera model, wherein optimal immunization of adult mice is followed by challenge of vaccinated animals with pathogenic V. cholerae. Recent studies in our laboratory have focused on the immunization phase of the model, defining immunization protocols which generate consistently strong antibody responses after mucosal administration of viable or inactivated V. cholerae (21) . The present report describes our progress with respect to the more chal-lenging task of circumventing the natural resistance of adult mice to gut colonization by V. cholerae.
We now report that it has indeed been possible to demonstrate long-term colonization and growth of V. cholerae in the guts of Sm-treated adult mice. Bacterial recoveries from washed intestinal tissues were found to correlate significantly with the levels of bacteria excreted in fecal pellets (FPs), which therefore provide a convenient way to monitor gut colonization. Depending on the infecting dose, V. cholerae can colonize naive Sm-treated hosts for at least 18 days, independent of the production of either cholera toxin (CT) or toxin-coregulated pili (TCP). Colonization is significantly curtailed in hosts that have been previously immunized with either viable or inactivated V. cholerae. Protection in this model is serogroup specific, and both serum and intestinal anti-LPS responses show strong inverse correlations with excretion of the challenge organisms.
MATERIALS AND METHODS

Animals.
Female BALB/c mice were purchased from Charles River Laboratories (Sulzfeld, Germany), individually marked, and generally used at 8 to 14 weeks of age. Occasional experiments were performed with 8-week-old female C57BL/6, C3H/HeN, and SJL mice from the same source. All animals in the study were treated and housed under specific-pathogen-free conditions as stipulated by the Ethical Committee for Laboratory Animals in Gothenburg.
Bacterial strains and culture conditions. V. cholerae strains were stored at Ϫ80°C in Luria-Bertani (LB) medium containing 20% glycerol and grown in LB medium at 37°C with agitation (150 rpm). When necessary for in vivo studies, Sm-resistant variants were selected by growth on LB agar plates containing Sm (200 g/ml). For immunization or challenge of mice, bacteria were grown to an optical density at 600 nm of 1.0 to 1.2, harvested by centrifugation, and washed twice in phosphate-buffered saline (PBS) before use. Wild-type V. cholerae strains H1 and N16961 are of the O1 serogroup (biotype El Tor, serotypes Ogawa and Inaba, respectively), whereas JBK70 is an atoxigenic mutant of the latter (16) . MO10 and AI-1838 are encapsulated serogroup O139 isolates. AF3 is an unencapsulated variant derived from AI-1838 (5), which was used for the isolation of O139 LPS. A tcpA::Km (kanamycin) derivative of AI-1838 (6) was used to investigate the role of TCP in colonization.
Formalin inactivation of V. cholerae. V. cholerae cultures grown and harvested as described above were washed twice with PBS and resuspended to a final concentration of 10 10 cells/ml in 1% formaldehyde-PBS. After incubation at 37°C for 2 h, the cells were washed twice and resuspended in PBS. Aliquots were plated to confirm sterility before addition of sodium azide and storage at 4°C. Formalin-killed bacterial suspensions were enumerated by using a Neubauer improved cell counting chamber (0.02 mm; Neubauer, Germany) and used within 7 days of preparation. Prior to immunization, the suspension was again washed twice in PBS and resuspended to the desired concentration.
Isolation of LPS. V. cholerae O139 LPS was extracted from strain AF3 (5) by using the phenol-water method of Westphal and Jann (32) and further purified as described elsewhere (21) . The protein contamination was Ͻ1%, as judged by using a Micro BCA protein assay kit (Pierce Biotechnology, Rockford, IL) and by determining the optical density at 280 nm relative to the total weight. V. cholerae O1 LPS was purchased from Sigma Aldrich (catalog no. L-0385) and is described as having Ͻ3% protein contamination.
In vivo experiments with V. cholerae. (i) Immunization with viable or inactivated V. cholerae. Mice were immunized (without any antibiotic treatment) as described elsewhere, using protocols previously shown to generate consistent serum and/or intestinal antibody responses (21) . Intranasal (i.n.) immunization was performed by administering 10 l of a PBS suspension of viable or formalinkilled bacteria dropwise to the external nares of each animal using an air displacement pipette. Mice to be immunized intraperitoneally (i.p.) or perorally (p.o.) were anesthetized lightly with isoflurane (Isoba Vet; Schering-Plough Animal Health, Stockholm, Sweden). Bacteria were then administered either in 0.2 ml of PBS or in 0.2 ml of an LB suspension containing 0.5 M NaHCO 3 . In all experiments, additional age-matched mice were set aside as untreated controls.
(ii) Challenge with viable V. cholerae. Naive or immunized mice were treated with Sm prior to challenge with pathogenic V. cholerae. Animals were provided with Sm-containing water ad libitum according to schedules described in the figure legends. Dosing was performed as described for p.o. immunization above; the number of viable bacteria administered was estimated retrospectively by viable counting.
(iii) Estimation of in vivo colonization. The duration and intensity of V. cholerae colonization was generally estimated by monitoring excretion of bacteria in FPs collected immediately after defecation. Four FPs (ca. 0.07 g) were collected into 1 ml of ice-cold PBS, homogenized, and plated in serial dilutions onto agar plates containing Sm. Initially, collection tubes were weighed prior to and after collection of the FPs to allow calculation of CFU per mg of fecal material, but this did not significantly alter the data and was deemed unnecessary.
In some experiments additional mice were infected to allow enumeration of bacteria persisting within the small intestine, cecum, and large intestine. Tissues were extensively rinsed in ice-cold PBS to remove debris and nonadherent vibrios and homogenized in 2 ml of PBS, and serial dilutions were plated onto agar plates containing Sm. (Previous testing had shown that recoveries from Sm plates were comparable to those obtained using thiosulfate/citrate/bile/sucrose plates.) Representative colonies were examined for agglutination using monoclonal antibodies directed against the relevant LPS. The limit of detection was 20 CFU; negative samples were given a value of 10 CFU for statistical analysis.
(iv) Competition studies. The colonization potentials of wild-type and tcpA::Km mutant bacteria were directly compared in competition experiments as described previously (6) . BALB/c mice of various ages were infected with a mixed suspension of the two strains, the input ratio being determined retrospectively by spreading the inocula on plates containing either Sm or both Sm and Km. After 24 h, the small intestines were excised and homogenized, and the resulting suspensions were again plated on both media for determination of the output ratios (ORs).
Analysis of antibody responses by ELISA. Serum and FP supernatant samples were collected before and after immunization to allow determination of the serum IgG and intestinal IgA antibody responses to LPS by an enzyme-linked immunosorbent assay (ELISA), as detailed elsewhere (21) . High-binding ELISA trays (Greiner, Germany) were sensitized with (O1 or O139) LPS (5 g/ml in PBS) overnight at 4°C. Samples (including a positive control of known activity) were titrated in threefold falling dilution and incubated for 4 h at 37°C. The following conjugates were used according to the manufacturers' instructions: goat anti-mouse IgA-horseradish peroxidase (HRP; Southern Biotech) and goat anti-mouse IgG-HRP (Jackson Immunoresearch Europe, Ltd.) (see Fig. 4A ) or goat anti-mouse IgG-HRP (Southern Biotech) (see Table 1 ). Because of variations in the immunoglobulin content of the fecal extracts, IgA ELISA titers were standardized per mg of total IgA as described previously (21) .
Statistical analyses. The Prism software system GraphPad 4.03 (GraphPad Software, Inc., San Diego, CA) was used for all statistical analyses. Multigroup comparisons were performed by using either one-way or two-way (repeated measurement) analysis of variance with Bonferroni's post test. The relationships between corresponding estimates were evaluated by using a Pearson correlation test. Two-sided P values of Ͻ0.05 were considered significant, and asterisks in the figures and table denote probability values (*, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001).
RESULTS
Oral infection of Sm-treated adult mice. To ascertain whether oral Sm treatment would predispose conventionally reared adult mice to colonization by V. cholerae, animals were given Sm in their drinking water and then orally inoculated with ca 10 10 Sm-resistant V. cholerae O139 strain MO10. At intervals thereafter fresh FPs were collected and processed to monitor the level of V. cholerae excretion. The Sm dosing regimen significantly influenced the colonization profile. All of the Sm-treated mice were initially colonized equally well (ϳ10 8 CFU per four FPs on day 2), whereas very few vibrios were excreted by the untreated controls (Fig. 1A) . Mice that were maintained on Sm postinoculation shed significantly higher numbers of vibrios for a longer period of time than those receiving Sm only prior to inoculation. All animals remained healthy for the duration of the experiment, showing no external signs of diarrhea, although in other experiments using a similar dose some occasional deaths did occur. The Sm-dosing regimen involving continuing exposure to antibiotic, beginning 24 h prior to administration of V. cholerae, was adopted for further studies.
Colonization by V. cholerae O1 and O139. We next compared the potential of V. cholerae O1 and O139 to colonize adult mice. Two groups of mice were treated with Sm and then infected with ϳ10
9 Sm-resistant wild-type O1 (El Tor strain H1) or O139 (MO10) bacteria; in our experience, all mice challenged with this lower dose remained healthy. For both strains, the FP burdens were ϳ10 8 CFU on day 2, and thereafter there was no significant difference in the colonization profiles (Fig. 1B) . The percentages of vibrio-positive mice over time did not differ significantly between the two strains (data not shown). Later experiments confirmed these findings and also showed that another Sm-resistant O139 strain, AI-1838, displayed a similar colonization profile (data not shown).
Recovery of V. cholerae from different regions of the gut. After oral infection of BALB/c mice with strain MO10, bacteria could be recovered from all parts of the intestine for several days ( Fig. 2A) . However, several logs fewer bacteria were associated with the small intestine compared to recoveries from the cecum and large intestine, and variation between the animals was also large. Statistical analysis of the bacterial burdens in these intestinal samples revealed significant correlations with the levels of FP excretion (P Ͻ 0.0001 for all comparisons and r ϭ 0.79 for the small intestine, 0.90 for the cecum, and 0.91 for the large intestine versus the FP). A limited repeat experiment surprisingly suggested that lower inocula of 10 8 and 10
6 bacteria established similar levels of intestinal colonization ( Fig. 2B to E) . With the lowest dose of 10 6 V. cholerae, the total recovery of bacteria on day 4 represented a 100-fold increase over the inoculum, indicating significant in vivo proliferation.
Impact of prior immunization on intestinal colonization by V. cholerae. Having demonstrated that both O1 and O139 serogroups can colonize the Sm-treated gut for at least a week, we investigated whether colonization would be curtailed in hosts which had been previously immunized. In other studies we defined regimens for mucosal (p.o. and i.n.) immunization that allow both viable and inactivated V. cholerae to generate consistent intestinal IgA anti-LPS responses in BALB/c mice (21) . Using these immunization schedules, an experiment was set up to compare the levels of protection induced by viable bacteria of the O139 strain AI-1838, administered by either the i.n. or p.o. routes. The i.p. route is commonly used in immunogenicity studies, and so another group was immunized by this route, while unvaccinated controls were set aside. At 4 weeks after the last immunization all of the animals were Sm treated and then challenged orally with a dose of ca. 10 9 bacteria of the immunizing strain.
No differences in the levels of excretion were apparent on day 2, but on day 4 the FP burdens were significantly reduced in all three groups of immunized mice, particularly those immunized i.n. (Fig. 3) . By day 5 there were Յ20 challenge bacteria detected in FPs collected from the majority of the immunized mice, irrespective of the immunization route, whereas FP burdens in control mice ranged from approximately 10 3 to 10 7 at that time. The control mice seemed to fall into two subgroups with dramatically different rates of clearance evident on days 5 and 6. Such variation had not been observed previously and was possibly related to the age of the animals at the time of challenge (see below). This variability 10 viable Sm-resistant V. cholerae O139 strain MO10 on day 0. Three of the groups received Sm-containing drinking water (5 mg/ml) before inoculation: group 1 (, n ϭ 6) and group 2 (Ⅺ, n ϭ 9) for 24 h and group 3 (F, n ϭ 8) for 48 h. Groups 2 and 3 also received Sm-water (0.2 mg/ml) after challenge. Animals in group 4 were left untreated (}, n ϭ 4). (B) Two groups of mice were Sm treated as described for group 2 above and then inoculated with either ca. 10 9 V. cholerae O1 strain H1 (F, n ϭ 5) or O139 strain MO10 (Ⅺ, n ϭ 5). In both panels, the numbers of viable bacteria recovered from four FPs are expressed as the geometric mean (GM) Ϯ the standard deviation (SD) log 10 CFU. The statistics for panel A were as follows. On day 2, bacterial recoveries from mice in groups 1 to 3 were significantly greater than those from control mice (P Ͻ 0.001); on day 4, only groups 2 and 3 were significantly greater (P Ͻ 0.001), and on day 7 only group 3 was significantly greater (P Ͻ 0.001). Bacterial excretion from group 1 was also lower than from groups 2 and 3 (P Ͻ 0.001) on day 4 and from group 3 (P Ͻ 0.01) on day 7. Repetitive oral immunization with inactivated V. cholerae elicits protective immunity. We have recently shown that mucosal immunization of adult mice with formalin-killed V. cholerae can elicit antibody responses comparable to those generated by live bacteria, provided extra doses are administered (21) . To ascertain whether the present model would be applicable to evaluation of inactivated vaccine candidates, we therefore immunized groups of mice with viable or formalin-killed bacteria of the O139 strain AI-1838, before later Sm treatment and homologous rechallenge. In the present study the vaccines were administered orally, and the vaccine dose increased to 5 ϫ 10 9 to boost host responses (21). The results indicated that vaccine viability is important for induction of host protective immunity. Mice immunized with two doses of viable V. cholerae showed significantly faster clearance of the challenge organisms than unvaccinated controls or mice given two doses of formalin-killed bacteria (Fig.  5) . However, six doses of killed vaccine conferred immunity to challenge, indicating that the model could be applied to the testing of inactivated vaccine candidates. Once again the control mice showed variable rates of bacterial clearance, with two animals showing ca. 40-to 100-fold lower excretion on day 6.
Review of model variables. The variable excretion patterns seen among control mice in the previous challenge studies represented a significant threat to the establishment of a robust model for evaluation of vaccine efficacy, and so attempts were made to refine the model system. To assess whether gut colonization would be more enduring or consistent in other mouse strains, C57BL/6, C3H/HeN, and SJL mice were Sm treated FIG. 4 . Impact of immunization route on immunogenicity of V. cholerae O139. Animals were immunized according to the schedules described in the legend to Fig. 3 . Serum IgG and standardized FP IgA responses were measured against O139-LPS by ELISA on day 56 (2 days before homologous rechallenge), and are expressed as the GM ϩ the SD log 10 titer. Asterisks denote significant differences from the control values.
FIG. 5. Viable and inactivated vaccines generate immunity to homologous rechallenge. Two groups of mice were orally immunized with either viable (OE, n ϭ 6) or formalin killed (fk; F, n ϭ 5) AI-1838 (5 ϫ 10 9 bacteria on days 0 and 28). A third group was given six similar doses of inactivated bacteria on days 0, 1, 2, 28, 29, and 30 (E, n ϭ 7), while a fourth group of mice was left untreated (f, n ϭ 6). All animals were Sm treated, beginning on day 57, and challenged on day 58 with ca. 10 9 AI-1838 bacteria. Each point shows the FP excretion (log 10 CFU) of a single mouse, while bars show the group GM Ϯ the SD. Asterisks denote significant differences from the control values. Returning to the specific issue of the inconsistent clearance of challenge organisms in BALB/c control mice, we next examined whether the age of the animals at the time of challenge might be an important factor. A key difference in the challenge study protocol is that mice are ca. 16 weeks of age when challenged, compared to ca. 8 weeks in the earlier colonization experiments. Older BALB/c mice might be comparatively refractory to colonization by V. cholerae, or perhaps the Sm dosing regimen is less efficient in older mice. An experiment was therefore set up to examine V. cholerae colonization in older naive BALB/c mice.
Since other studies (21) had revealed that the peak of the intestinal IgA anti-LPS response occurs on days 35 to 42 using the vaccination schedules used above, we decided to alter the timing of the challenge inoculum to day 42, i.e., 2 weeks (rather than 4) after secondary immunization. This would mean that henceforth the mice would be 14 weeks at the time of challenge, and so mice of this age were used for the present study. Two Sm dosing regimens were compared: the standard regimen used hitherto and one involving a longer period (48 h) of dosing prechallenge and maintenance on a higher concentration (1 mg/ml) of Sm postchallenge. Conceivably, the higher doses might retard the reacquisition of a normal microflora, thereby allowing prolonged persistence of the challenge organisms. However, the colonization profiles seen in the older mice were not significantly different from those previously observed in younger animals. The modified Sm dosing protocol resulted in slightly but consistently elevated FP excretion of the challenge organisms and so was adopted for routine future use, although the variability within each group was not reduced (data not shown).
Finally, we tested whether a lower challenge dose might allow a more rapid expression of host immunity and yet still be sufficient to provide consistent colonization of unimmunized hosts. The data shown in Fig. 2 were encouraging in this respect. Another experiment with the more intensive Sm dosing regimen therefore sought to directly compare colonization profiles after challenge of 14-week-old mice with doses of 10 9 or 10 7 bacteria (Fig. 6) . The excretion profile after the higher dose was similar to that seen in earlier studies, with considerable variability at each time point. For example, on day 6 there was an almost 700-fold range in bacterial recoveries in FPs, with 5.6 ϫ 10 3 to 32 ϫ 10 3 CFU recovered from three mice but 1.9 ϫ 10 7 to 3.8 ϫ 10 7 CFU recovered from the other two animals. Counterintuitively, FP excretion was significantly higher after the lower challenge dose (Fig. 6 ). The level of excretion was maintained above 10 7 CFU even on day 8, and the variability within this group was much reduced (15-fold range in recoveries on day 6). Later experiments confirmed these findings and showed that colonization continues for at least 17 days in unimmunized mice (see Fig. 8 ). Other studies confirmed that lowering the challenge dose did not affect the in vivo distribution of the challenge organisms, which were still primarily localized to the cecum and large bowel (data not shown).
Colonization does not depend on production of CT or TCP. CT and TCP are critical virulence determinants that enable V. cholerae to establish infection and disease in the human intestine (9, 16, 29) . To evaluate the significance of these factors in our modified model (more intensive Sm treatment regimen and lower challenge inoculum), we assessed the colonization potential of mutant strains unable to express either factor. FP excretion patterns from animals fed N16961 or its atoxigenic derivative JBK70 were identical (Fig. 7A) , indicating that CT is not essential for persistence in the adult mouse gut.
A preliminary study examining FP excretion profiles from mice given wild-type or mutant V. cholerae suggested that colonization was also independent of TCP expression (data not shown). This was unexpected given earlier findings in the IMCM, which have shown dramatic attenuation and colonization impairment associated with mutations affecting TCP expression (6, 30) . We therefore conducted competition experiments, to compare the colonization potential of a tcpA::Km mutant strain with that of the wild type in mice of different ages. As anticipated, recoveries of mutant bacteria were greatly reduced in infant mice, with a median OR of 11,400:1 in favor of the wild type (Fig. 7B) . In contrast, there was again little difference in the ratios of the two strains present in the small intestines of adult mice (median OR 2.1:1). Mice of FIG. 6 . Effect of challenge inoculum on intestinal colonization by V. cholerae O139. Two groups of 14-week-old BALB/c mice were treated with the more intensive Sm regimen (5 mg of Sm/ml for 48 h prior to inoculation and 1 mg/ml after challenge). The animals were inoculated with either 10 7 (f, n ϭ 6) or 10 9 (, n ϭ 5) bacteria of the MO10 strain; graphs show FP excretion (GM Ϯ the SD log 10 CFU). Asterisks denote significant differences between the two groups. Protective immunity is serogroup specific and correlates with host immune responses. Using the modified model, we returned to the question of whether preimmunization could significantly curtail the colonization of V. cholerae. If so, it would be important to ascertain whether protective immunity was serogroup specific, as is inferred to be the case in humans. Two groups of mice were immunized i.n. with viable V. cholerae O1 (strain H1) or O139 (strain AI-1838), using a schedule previously shown to generate comparable immune responses to the two serogroup antigens (21) . Age-matched controls were left unimmunized. Two weeks after the (day 28) booster immunizations, each of the three groups was subdivided for homologous or heterologous oral challenge with V. cholerae O1 or O139. Systemic and intestinal anti-LPS responses were measured by ELISA.
Confirming our earlier findings using a higher challenge dose (Fig. 1B) , the colonization profiles of the O1 and O139 challenge strains were very similar in unimmunized hosts (Fig.  8) . FP burdens were consistent within both control groups, with excretion of ca. 10 5 bacteria persisting through to day 17. These patterns were not significantly altered by prior immunization with V. cholerae of heterologous serogroup, whereas vaccination did confer significant immunity to homologous rechallenge. This was manifest as a shorter period of colonization, which was particularly evident with the O139 challenge strain, where excretion of challenge bacteria was not detectable beyond day 14. Despite this, there was still no early reduction in bacterial load in the first few days after challenge (Fig. 8) . The serogroup restriction of the protective host immune response has been confirmed in a more recent study.
The immunization protocol elicited strong antibody responses to homologous LPS, but titers to heterologous LPS were minimal and comparable to those seen in control mice (Table 1) . Serum and intestinal anti-LPS titers measured in prechallenge (day 41) samples were compared to the FP bacterial recoveries on day 59 (day 17 postchallenge). Highly significant inverse correlations were observed between both IgG and IgA antibody levels and CFU recovered from FP, after either O1 or O139 challenge (Table 1) .
DISCUSSION
Sm dosing regimens that were initiated prior to infection and maintained thereafter made mice receptive to intestinal colonization by V. cholerae, making it feasible to consider a model which would allow direct evaluation of vaccine efficacy. From both time and cost perspectives it was a great advantage to be able to monitor colonization by repeated FP sampling of the same animals. Comparison of FP excretion patterns in immunized and control hosts demonstrated the beneficial impact of vaccination. In this respect, the model is widely applicable, with early studies revealing protection induced by i.n., p.o., or i.p. administration of live or killed vaccines (Fig. 3 and 5) . The protective potential of vaccines given either i.n. (Fig. 8) or p.o. (E. Nygren, S. R. Attridge, and J. Holmgren, unpublished data) was later confirmed in the improved model system, in which a much lower challenge dose paradoxically resulted in more sustained and consistent colonization of naive hosts. In both studies, vaccination conferred serogroup-restricted protection, reflecting the situation thought to pertain to humans.
During the course of these studies, Olivier et al. (22, 23 ) described a similar model that also relies upon Sm treatment, but of juvenile (ϳ5-week-old) C57BL/6 mice rather than the adult (8-to 14-week-old) BALB/c mice used in our studies. In the system of Olivier et al., a dose of only 10 8 bacteria represents a 100% lethal dose, with most mice succumbing within (22, 23) . Differences in the age and strain of the host and in the bacterial challenge strains make it difficult to compare the two systems. In our studies, oral challenge with 10 9 V. cholerae was uniformly well tolerated, and even at a challenge dose of 10 10 bacteria few deaths occurred. We also observed a transient colonization of the small intestine, but very few bacteria were recovered from this site relative to the much greater numbers persistently isolated from the large bowel. Given the predilection of V. cholerae for the human small intestine, this limits the extent to which our new model can be considered to represent human infection. Nevertheless the bacteria clearly replicate within the murine gastrointestinal tract. Recoveries of challenge organisms in different gut tissues (Fig. 2 ) or in fresh FPs ( Fig. 6 and 8) were consistently greater than the initial challenge inoculum for periods of 4 or 8 days, respectively. In neither our model nor that of Olivier et al. (22, 23) was V. cholerae colonization dependent on the expression of CT, but this was not unexpected. Atoxigenic live cholera vaccines effectively colonize the human gut (9, 16) , and CT production is not required for colonization of the infant mouse intestine (30) . Prolonged persistence of wild-type V. cholerae did not d When day 41 sera and intestinal anti-LPS titers in control animals and in mice subjected to homologous rechallenge were analyzed in relation to day 59 FP excretion levels, highly significant inverse correlations were detected after both O1 and O139 challenge.
cause diarrhea in our system, and again this is not surprising. There are many reports of investigators feeding tremendous numbers of pathogenic vibrios to adult mice without any adverse effects, and germfree mice remain healthy after monocontamination with toxigenic V. cholerae (7, 27) . Conventional mice even tolerate oral administration of high doses of CT without signs of diarrhea; while they respond with profuse fluid secretion in the small intestine, the murine colon has an enormous capacity for fluid reabsorption (15) . Although the present absence of diarrhea is an obvious inconsistency with the human infection, overt disease is not necessary for evaluation of cholera vaccines, as our present studies demonstrate.
However, the finding that colonization in our model is also independent of TCP expression was unexpected. Studies in the IMCM had revealed the pivotal role of TCP in colonization (6, 30) and prompted later volunteer trials which extended this finding to the human infection (9, 29) . Our present data show that mice become refractory to colonization somewhere between 3 and 14 days of age, although the underlying basis remains unknown. This is consistent with the finding by Olivier et al. that TCP expression is not required for colonization of mice at about 5 weeks of age (22, 23) .
Some progress has been made with respect to defining the nature of protective host immunity in the new model. Our studies have consistently detected strong anti-LPS responses, including locally produced intestinal IgA antibodies, in groups of immunized mice capable of restricting the colonization of challenge bacteria. This is encouraging given our present understanding of the nature of protective immunity in humans. Antibacterial immune protection after infection or oral immunization with live or killed cholera vaccines appears to be mediated mainly if not exclusively by anti-LPS antibodies which mediate enteric defense and which are reflected serologically by serum vibriocidal antibodies (17) . Presumably as a result, vaccine-or exposure-derived protective immunity is serogroup restricted, both in humans and in our present model system. It is worth noting that, while the vaccine potential of TCP remains to be resolved, the inactivated bacteria comprising the whole-cell component of the current internationally licensed oral cholera vaccine do not express TCP and yet provide substantial levels of protection. In the present context, the irrelevance of TCP for adult mouse colonization precludes further work to examine whether expression of such pili might enhance the immunogenicity of inactivated V. cholerae. This finding does not, however, invalidate the model as a system for studying the induction and protective potential of antibody responses to LPS or other (Nygren et al., unpublished) antigens. Indeed, the rationale for the development of the current CT B-supplemented whole-cell vaccine formulation was based on studies in the rabbit ligated ileal loop model (11), a closed system that would no longer be considered the most appropriate cholera model.
The factors that determine the temporal expression of the protective host immune response remain obscure. In our initial studies using a challenge dose of 10 9 bacteria there was clearly a lag period of several days before the expression of immunity in vaccinated hosts. One interpretation is that the vaccineinduced immune response was insufficient to prevent some colonization at such a high inoculum. For this reason, we tested the possibility that a lower challenge dose might allow demonstration of a more immediate expression of host (possibly sterilizing) immunity. That a 100-fold lower challenge dose should result in more sustained and much more consistent colonization of unimmunized mice was surprising and remains unexplained. Possibly, the higher challenge dose generates an inflammatory gut response with stimulation of innate immunity that inhibits V. cholerae persistence. Such responses have been described in patients with severe cholera (8, 24) .
Nevertheless, the fortuitous improvement in the duration and reproducibility of colonization observed using the lower challenge dose made the model more robust and provided a longer window for expression of protective immunity. Intriguingly, however, host immunity was clearly still delayed, even more so than in our early experiments with the higher challenge dose. At present, vaccine-induced protection is evidently not sufficient to mediate sterilizing immunity in this model; rather, our immunization schedules seem to prime the host, such that the challenge inoculum then elicits a memory response capable of reducing the period of colonization. In this context, while the change to a lower challenge dose is clearly advantageous in terms of providing more reliable and sustained colonization, there might be a concomitant disadvantage. If the challenge inoculum indeed provides an important stimulus for a presensitized immune system, then any significant reduction in the challenge dose would compromise its immunological impact. Further studies are needed to elucidate this issue.
In conclusion, we describe a convenient new model for direct evaluation of the protective (anticolonization) potential of cholera vaccines. V. cholerae colonizes and proliferates (albeit ectopically) within the guts of Sm-treated adult mice, with FP sampling providing a convenient indicator of bacterial persistence. Vaccination with either viable or inactivated V. cholerae confers immunity to homologous rechallenge, with significant inverse correlations between the strength of host anti-LPS responses and the persistence of challenge organisms.
